Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of anti-infective products. The company primarily focuses on addressing gastrointestinal infections and related diseases that have limited treatment options. Its notable late-stage product candidates include fidaxomicin, an antibacterial drug designed for the treatment of Clostridium difficile-associated diarrhea, and Pruvel (prulifloxacin). In addition to these, Optimer's portfolio comprises CEM-101, OPT-822/OPT-821 combination therapy, and OPT-88. The company aims to create therapies that significantly improve patient outcomes and alleviate the burden of infectious diseases.
Top Stages
https://crunchbase.com/organization/***
1 past transactions
Cempra
Series B in 2007
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.